<DOC>
	<DOCNO>NCT01198496</DOCNO>
	<brief_summary>1 . Objectives Hypothesis 1 . Objectives : This study evaluate whether strict BP management useful prevention recurrent stroke . Hypertensive patient history stroke treated stepwise multi-drug therapy achieve stricter BP target &lt; 120/80 mmHg strict BP control group less stricter BP target &lt; 140/90 mmHg &lt; 130/80 mmHg patient current DM/CKD/MI standard BP control group . The participant BP treatment achieve respective BP target follow recurrence stroke . The study continue number patient first recurrent stroke reach total 330 two group . The occurrence rate recurrent stroke compare two group . 2 . Hypotheses The incidence recurrent stroke low strict BP control group lower BP target : &lt; 120/80 mmHg* standard BP control group BP target &lt; 140/90 mmHg &lt; 130/80 mmHg current DM/CKD/MI patient hypertension . 2 . Study design This multicenter , randomize , open-label study . The study consist screen period , titration period follow-up period . The screening period period date consent enrollment date . Hypertensive patient history stroke randomly assign either strict BP control group target &lt; 120/80 mmHg standard BP control group target &lt; 140/90 mmHg without current DM , CKD MI &lt; 130/80 mmHg current DM , CKD MI . The titration period period find treatment achieves target BP , 24 week maximum . Patients treat stepwise multi-drug therapy use angiotensin-receptor antagonist , diuretic , calcium channel blocker aldosterone antagonist . The participant observe BP management respective BP target . The study continue number patient first recurrent stroke reach total 330 two group . The follow-up period 3 year . The recurrent rate stroke group compare various aspect , strict BP management investigate usefulness prevention recurrent stroke .</brief_summary>
	<brief_title>Recurrent Stroke Prevention Clinical Outcome Study</brief_title>
	<detailed_description>Rationale Study Duration Predicting strict BP control reduce relative risk recurrent stroke 30 % planned observation period 3 year , number participant necessary detect recurrent stroke rate 2.5 % /year 7.5 % /3 year 2482 patient per group detection power 90 % α-error 0.05 . A drop-out rate estimate 20 % . Therefore , study continue 3 year total 330 patient recurrent stroke group identify . Rationale Dosing Regimen One ARB , losartan , choose Step 1 therapy , angiotensin II receptor blocker ( ARB ) prefer first line anti-hypertensives . Furthermore , stepwise combination therapy BP lower drug diuretic , hydrochlorothiazide , calcium channel blocker , amlodipine , use , Japanese guideline recommend combination BP control prevention recurrent stroke . ( Step 2 Step 5 ) . Finally ( Step 6 ) , selective aldosterone antagonist , spironolactone , add treatment refractory hypertensive patient whose BP reach target . Treatment Plan The dosage study drug determine accord package insert drug . Patients treat antihypertensive agent treat one antihypertensive agent enrollment start Step 1 . Patients treat two antihypertensive agent enrollment start Step 2 . In principle , treatment duration 4 week step .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Participants include essential hypertension history stroke satisfy follow criterion : Outpatient Onset stroke ( cerebral infarction/cerebral hemorrhage ) occur 30 day 3 year prior date consent . Drug adherence ≧80 % screening period . Mean 2 baseline BP measurement ( measure outpatient clinic ) within 30 day prior date consent either 180 &gt; SBP ≧130 mmHg 110 &gt; DBP ≧80 mmHg ( untreated 3 anti hypertensive agent patient ) . Cerebral infarction severity 3 less modify Rankin scale . Patient meet one follow criterion exclude study . Women pregnant , possible pregnant , breastfeed Possible secondary hypertension Severe hypertension ( grade III great ) baseline SBP ≧180 mmHg DBP ≧110 mmHg ) Myocardial infarction undergo angioplasty occur within 3 month prior screen . Current previous heart failure NYHA classification class III , EF le 35 % Severe bilateral carotid stenosis major cerebral artery occlusion Severe paralysis due stroke ( modify Rankin scale ≧ 4 ) Current renal dysfunction ( serum Cr ≧ 2.0 mg/dL right date consent ) Current hepatic dysfunction AST ALT value ≧ 100 IU/mL right date consent Refractory hypertension treat four antihypertensive drug Hypersensitivity allergy losartan angiotensin II receptor blocker , hydrochlorothiazide , amlodipine sulfonamide derivative Major surgery plan study period Participants clinical study within last 30 day Current malignancy ( previous malignancy within 5 year end treatment ) exclude squamouscell skin cancer Previous current subarachnoid hemorrhage Definitive dementia 12 ) ( base clinical diagnosis ) Patients difficulty sign consent agree provide consent Patients judge unsuitable participate study primary investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>hypertension</keyword>
	<keyword>stroke</keyword>
	<keyword>blood pressure</keyword>
</DOC>